Patrick Hagen
Hematology & Oncology · Maywood, ILNPI 1265725592
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $113,298 of the $141,253 with a category attached, or 80.2%. Sanofi accounts for 61.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $49,157 and has fallen 69.2% since, to $15,133 in 2025. Among hematology & oncology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $1207.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$87K
- E.r. Squibb & Sons, L.L.C.$28K
- Bristol Myers Squibb$17K
- Sanofi-aventis U.S. LLC$6K
- Adaptive Biotechnologies Corporation$2K
- National Marrow Donor Program$696
- plus $553 from 8 others
Across 77 payments — averaging $7940.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$212K
- Takeda Pharmaceuticals U.S.A., Inc.$113K
- Gilead$101K
- AbbVie$76K
- Janssen Research & Development, LLC$51K
- GSK$30K
- plus $28K from 2 others
What the payments were for
- Consulting fees$20,63015%
- Speaking & faculty fees$113,29880%
- Travel & lodging$3,3672%
- Food & beverage$3,8693%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 46 | $87,472 |
| E.r. Squibb & Sons, L.L.C. | 19 | $28,357 |
| Bristol Myers Squibb | 14 | $16,616 |
| Sanofi-aventis U.S. LLC | 3 | $5,888 |
| Adaptive Biotechnologies Corporation | 13 | $1,670 |
| National Marrow Donor Program | 4 | $696 |
| Pfizer | 11 | $202 |
| Akcea Therapeutics, Inc. | 1 | $122 |
| Novartis | 1 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $55 |
| AstraZeneca | 1 | $43 |
| Merck | 1 | $20 |
| GSK | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$141,253 in reported general payments places this provider in the 90th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 317 | $5,895,814 |
| Lenalidomide | 152 | $2,307,408 |
| CalquenceAcalabrutinib Maleate | 66 | $909,547 |
| PomalystPomalidomide | 28 | $612,059 |
| JakafiRuxolitinib Phosphate | 31 | $530,561 |
| BrukinsaZanubrutinib | 24 | $324,991 |
| VenclextaVenetoclax | 31 | $181,285 |
| NinlaroIxazomib Citrate | 14 | $173,042 |
| Imatinib Mesylate | 22 | $43,340 |
| EliquisApixaban | 12 | $14,103 |
| XareltoRivaroxaban | 12 | $6,428 |
| Acyclovir | 96 | $2,145 |
| CholestyramineCholestyramine (With Sugar) | 13 | $1,238 |
| ValacyclovirValacyclovir Hcl | 12 | $725 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 63 | $413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $16,616 | $5,895,814317 claims |
| AstraZenecaCalquence | $43 | $909,54766 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $28,357 | $612,05928 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $55 | $173,04214 claims |
| PfizerEliquis | $202 | $14,10312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Maywood
- Mohamad Khair KhasawnehMaywood$998K
- Agne PanerMaywood$75K
- Scott SmithMaywood$55K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.